Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib

We have carefully read the article by Dr. Cascone et al. in which they report the results of a phase 2 study evaluating the role of the induction therapy with cisplatin plus docetaxel, followed by a surgery and erlotinib in patients with resectable non-small cell lung cancer (NSCLC). This study has been registered as NCT00254384 and the data presented in the aforementioned article correspond to long-term efficacy results (1).